Pharma BD Deal Intelligence
Forest paid $580M for Cerexa's ceftaroline (Teflaro), which reached the market as promised but never became the blockbuster the price implied. Analysts modeled $150-200M peak sales, yet the drug limped to just $22.4M by its second full year, and by 2016—six years post-launch—had only reached ~$134M, never triggering the $100M sales milestone.
Ceftaroline (Teflaro) reached market as promised but never hit the sales projections that justified the price — a durable niche antibiotic, not the blockbuster Forest paid for.
Full analysis, sources & comparables →Ceftaroline is an important late-stage development product that can address serious and life-threatening infections in the hospital setting including MRSA. -…
Forest to acquire privately-held biotech Cerexa for $480M; lead compound ceftaroline anticipated to enter late-stage trials in 2007 with potential market entry…
Forest Labs acquires pharma company Cerexa for up to $580M, including the $480 million upfront and a $100 million milestone tied to ceftaroline sales.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Antibiotics; ceftaroline (Teflaro); $480M + up to $100M milestone
Ceftaroline (Teflaro) reached market as promised but never hit the sales projections that justified the price — a durable niche antibiotic, not the blockbuster Forest paid for.
Assessment window: 15yr post-close.
80K US cases/yr
Methicillin-resistant Staphylococcus aureus (MRSA) drives serious skin/soft-tissue infections, hospital-acquired pneumonia, bloodstream infections, and bacteremia; resistance to beta-lactams forced reliance on vancomycin, daptomycin, and linezolid. Community-acquired bacterial pneumonia (CABP) remains a leading infectious cause of US hospitalization. Both indications were the lead label sought for ceftaroline at the time of the Cerexa acquisition.
At the December 2006 deal close, the anti-MRSA hospital antibiotic market was anchored by generic vancomycin (Vancocin), Pfizer/Wyeth's Zyvox (linezolid, oxazolidinone, oral/IV), and Cubist's Cubicin (daptomycin, lipopeptide, IV) which had launched in 2003 and was rapidly taking share for cSSSI and bacteremia. Pfizer/Wyeth's Tygacil (tigecycline, glycylcycline) had launched in 2005 for cSSSI and intra-abdominal infections. Cerexa's lead compound ceftaroline was a next-generation broad-spectrum cephalosporin — the first beta-lactam with reliable in-vitro MRSA activity — positioning it to displace vancomycin's empirical role for cSSSI and CABP while remaining within the familiar cephalosporin class for hospital prescribers. Forest paid $480M cash plus a $100M milestone tied to ceftaroline US sales exceeding $500M in any 12-month period within five years of launch, pulling in worldwide rights ex-Japan plus an option on a third early-stage injectable antibiotic. Forest CEO Howard Solomon said the company had 'a high degree of confidence in the successful commercialization and financial prospects for ceftaroline given the strength of the existing clinical data and the clinical need for a next-generation hospital-based antibiotic.' Ceftaroline (Teflaro) gained FDA approval October 29, 2010 for cSSSI and CABP, but commercial uptake was constrained by hospital antibiotic stewardship and price sensitivity versus generic vancomycin — the milestone was widely viewed as unlikely to trigger. (Source: FierceBiotech / SEC 8-K filing)
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Forest Laboratories, Inc. / Cerexa Inc. (this deal) | 2006 | $580M | 47 |
| Forest Laboratories, Inc. / Clinical Data, Inc. | 2011 | $1.2B | 37 |
| Forest Laboratories, Inc. / Aptalis Pharma Inc. | 2014 | $2.9B | 25 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |